Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
17 Junio 2024 - 3:10PM
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the
“Company”), a pre-clinical-stage pharmaceutical company focused on
the development and commercialization of Telomir-1 as the first
novel small molecule to lengthen the DNA’s protective telomere caps
as a potential treatment for age-related conditions, today
announced that its scientific advisor, Adam Kaplin, M.D., Ph.D.,
was invited by InSilicoTrials to speak on its panel discussion on
June 17, 2024, at the DIA Global Annual Meeting. Along with his
fellow panelists, Dr. Kaplin will discuss case studies based on his
experience using generative AI to provide data modeling solutions
to reduce the time and cost of therapeutic studies while upholding
strict patient safety standards.
“The opportunity to participate in the panel,
titled, ‘Are Human Patients Needed for Clinical Trials, Tomorrow?’
will allow me to both share my experience using generative
AI-powered data modeling in therapeutic trials and to learn from my
peers about their experiences,” said Dr. Adam Kaplin, scientific
advisor to Telomir. “By partnering with companies like
InSilicoTrials, Telomir is able to utilize these technologies to
enhance and expedite drug dosing, trial performance, and patient
safety while reducing the time and cost of their trials. Using
generative AI technologies has the potential to move new therapies
into the market much more quickly and safely, improving specific
research and development activities by up to 90%.”
DIA 2024 is the largest global,
multidisciplinary event for the professionals involved in the
discovery, development, and lifecycle management of
pharmaceuticals, biotechnology, medical devices, and related
products.
To be added to the Telomir Pharmaceuticals email
distribution list, please email telomir@kcsa.com with TELO in the
subject line.
About Telomir Pharmaceuticals,
Inc.Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a
pre-clinical-stage pharmaceutical company focused on the
development and commercialization of Telomir-1 as the first novel
small molecule to lengthen the DNA’s protective telomere caps in
order to potentially reverse age-related conditions. Telomeres are
the protective end caps of a chromosome made up of DNA sequences
and proteins. As humans age, telomeres shorten, with metal
reactivity accelerating the process, which presents us with an
increased chance of contracting a number of degenerative and
age-related diseases. Telomir’s goal is to develop and
commercialize Telomir-1 (which is proposed to be dosed orally) for
a broad range of age-related inflammatory conditions such as
osteoarthritis.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the
Nobel Prize in Physiology or Medicine in 2009 for the discovery of
how chromosomes are protected by telomeres and the enzyme
telomerase.
About InSilicoTrialsInSilicoTrials aims
to become the leading problem solver in drug development by
leveraging computational modeling and simulation (in silico)
techniques. Using AI and advanced predictive technologies, we
support emerging biotech and pharma companies by generating robust
digital evidence and clinical outcomes. Our in silico methods
reduce R&D time and costs, offering virtual patient and
AI-enhanced trial accuracy, cloud-based simulations for
comprehensive virtual assessments & regulatory-compliant data
to support clinical programs.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTSThis press release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. These forward-looking statements
include, without limitation, statements regarding completion,
timing and anticipated size of the initial public offering and the
expected commencement of trading on the Nasdaq.
Any forward-looking statements in this press
release are based on Telomir's current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the potential use of
the data from our studies, our ability to develop and commercialize
Telomir-1 and the aging process and safety of Telomir-1. These and
other risks concerning Telomir's programs and operations are
described in additional detail in its Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, which is on file with
the SEC. Telomir explicitly disclaims any obligation to update
any forward-looking statements except to the extent required by
law.
For further information, please contact:
KCSA Strategic Communications Phil
Carlsontelomir@kcsa.comTelomir
Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558
Telomir Pharmaceuticals (NASDAQ:TELO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Telomir Pharmaceuticals (NASDAQ:TELO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024